1159500-34-1
1159500-34-1
Chemical Structure
Selatogrel
Synonym(s): ACT-246475
- CAS No.: 1159500-34-1
- Formula:C28H39N6O8P
- Molecular Weight:618.62
IUPAC Name: ((R)-3-(4-(butoxycarbonyl)piperazin-1-yl)-2-(6-((S)-3-methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carboxamido)-3-oxopropyl)phosphonic acid
InChIKey: FYXHWMQPCJOJCH-GMAHTHKFSA-N
SMILES: O=C(N1CCN(CC1)C(OCCCC)=O)[C@H](CP(O)(O)=O)NC(C2=CC(N3C[C@H](CC3)OC)=NC(C4=CC=CC=C4)=N2)=O
Biological Activity: Selatogrel (ACT-246475) is a reversible and selective P2Y12 receptor antagonist which inhibits platelet aggregation with an IC50 of 8 nM. Selatogrel exhibits antithrombotic efficacy[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Selatogrel | 99.75% | Selatogrel (ACT-246475) is a reversible and selective P2Y12 receptor antagonist which inhibits platelet aggregation with an IC50 of 8 nM. Selatogrel exhibits antithrombotic efficacy. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Selatogrel (Standard) | ≥98% | Selatogrel (Standard) is the analytical standard of Selatogrel (HY-109122). This product is intended for research and analytical applications. Selatogrel (ACT-246475) is a reversible and selective P2Y12 receptor antagonist which inhibits platelet aggregation with an IC50 of 8 nM. Selatogrel exhibits antithrombotic efficacy. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Selatogrel hydrochloride | Selatogrel (ACT-246475) is a reversible and selective P2Y12 receptor antagonist which inhibits platelet aggregation with an IC50 of 8 nM. Selatogrel exhibits antithrombotic efficacy. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
BX048 | BX048 is an active compound. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
BX 667 | BX 667 is an orally active reversible P2Y(12) receptor antagonist. BX 667 attenuates thrombosis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
ACT-281959 | ACT-281959 is an orally active prodrug of Selatogrel (HY-109122), a P2Y12 receptor antagonist. ACT-281959 can inhibit platelet aggregation and can be used for the research of cardiovascular disease. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
LEI-401 | 99.73% | LEI-401 is a first-in-class, selective, and CNS-active NAPE-PLD (N-acylphosphatidylethanolamine phospholipase D) inhibitor, with an IC50 of 27 nM. LEI-401 modulates emotional behavior in mice. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Histamine H4 receptor antagonist-1 | 99.57% | Histamine H4 receptor antagonist-1 is an antagonist of histamine H4 receptor extracted from patent WO2010108059A1 compound 60. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
AA10 | AA10 is a potent and irreversible transglutaminase 2 (TG2) inhibitor for cancer research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
E3 Ligase Ligand-linker Conjugate 91 | E3 Ligase Ligand-linker Conjugate 91 is a conjugate of E3 ligase ligand and linker, consisting of (S,R,S)-AHPC (HY-125845) and the corresponding Linker. (S,R,S)-AHPC is a VH032-based von Hippel-Lindau (VHL) ligand that recruits VHL proteins. E3 Ligase Ligand-linker Conjugate 91 can be used as a key intermediate for the synthesis of complete PROTAC molecules. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
ATR-IN-30 | ATR-IN-30 (Compound 5) is a selective ATR ligand, and can be used for synthesis of ATR PROTACs, such as PROTAC ATR degrader-2 (HY-161615). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(Rac)-BX 048 | (Rac)-BX 048 is a BX 048 racemate. BX 048 is a P2Y12 receptor antagonist. BX 048 inhibits ADP-induced platelet aggregation in human, dog and rat whole blood. BX 048 also inhibits Arachidonic acid (HY-109590) induced platelet aggregation (IC50 of 15 μM). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Caroff E, et al., 4-((R)-2-{[6-((S)-3-Methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}-3-phosphonopropionyl)piperazine-1-carboxylic Acid Butyl Ester (ACT-246475) and Its Prodrug (ACT-281959), a Novel P2Y12 Receptor Antagonist with a Wider Therapeutic Window in the Rat Than Clopidogrel. J Med Chem. 2015 Dec 10;58(23):9133-53. [Content Brief]
